Objective: Central neurocytomas (CNs) are rare, and this has resulted in a paucity of information and a lack of clarity regarding their optimal management. This study aimed to explore individual treatment strategies for CNs and the benefits of these strategies for patients. Methods: This single-center study retrospectively analyzed data from 67 patients with CNs who underwent surgery. Based on the extent of resection, patients were divided into complete and incomplete resection groups. The patients were followed, and overall survival (OS) and progression-free survival (PFS) were determined. Results: Of 55 patients (82.1%) who underwent complete resections, 24 received radiotherapy (24/55, 43.6%). Of 12 patients who underwent incomplete resections, 9 (9/12, 75.0%) received radiotherapy. The OS (p = 0.003) and PFS (p = 0.006) intervals were significantly longer in the complete resection group than in the incomplete resection group. Postoperative radiotherapy did not affect OS (p = 0.129) or PFS (p = 0.233) in the complete resection group. In the incomplete resection group, postoperative adjuvant radiotherapy prolonged patient survival significantly (p = 0.021). PFS was significantly longer among patients who underwent complete resection without radiotherapy than in those who underwent incomplete resection followed by radiotherapy (p = 0.034). Functional dependence on admission, which was defined as a Karnofsky Performance Status score <70, was an independent risk factor associated with long-term survival in patients with CN. Postoperative complications were not associated with the amount of tumor resected. The prognosis of patients aged ≥ 50 years was relatively poor. The atypical CN recurrence rate was relatively high (7.8%). Conclusions: To protect function as much as possible, complete tumor resection should be the first choice of treatment for CN. After gross total resection, adjuvant radiotherapy is not acceptable. Postoperative adjuvant radiotherapy improves the prognosis of patients who have undergone incomplete tumor resections. Adjuvant radiotherapy is not recommended after complete resections of atypical CNs, and close follow-up with imaging is required. Our findings can help guide decision-making regarding the treatment of CNs and could potentially maximize the benefits of treatment for patients with CN.

中文翻译：

---

中枢神经细胞瘤的个体治疗决定。

目的：中枢神经细胞瘤（CNs）很少见，这导致信息匮乏且缺乏关于其最佳管理的明确性。这项研究旨在探讨中枢神经系统的个体治疗策略以及这些策略对患者的益处。方法：这项单中心研究回顾性分析了67例接受手术的CN患者的数据。根据切除范围，将患者分为完全切除组和不完全切除组。对患者进行随访，确定总生存期（OS）和无进展生存期（PFS）。结果：55例患者（82.1％）接受了完全切除，其中24例接受了放疗（24 / 55，43.6％）。在接受不完全切除的12例患者中，有9例（9/12，75.0％）接受了放疗。OS（p = 0.003）和PFS（p = 0。006）完全切除组的间隔明显长于不完全切除组。完全切除组的术后放疗未影响OS（p = 0.129）或PFS（p = 0.233）。在不完全切除组中，术后辅助放疗显着延长了患者的生存期（p = 0.021）。在没有放疗的情况下进行完全切除的患者的PFS明显比在放疗后的不完全切除患者中的PFS更长（p = 0.034）。对入院的功能依赖性（定义为Karnofsky绩效状态评分<70）是与CN患者长期生存相关的独立危险因素。术后并发症与切除的肿瘤数量无关。≥50岁的患者的预后相对较差。非典型CN复发率较高（7.8％）。结论：为尽可能保护功能，彻底切除肿瘤应成为CN治疗的首选。完全切除后，不能接受辅助放疗。术后辅助放疗改善了肿瘤切除不完全的患者的预后。不典型的CN完全切除后，不建议进行辅助放疗，并且需要密切随访影像学检查。我们的发现可以帮助指导有关中枢神经系统治疗的决策，并可能最大程度地提高对中枢神经系统患者的治疗益处。彻底的肿瘤切除应该是CN治疗的首选。完全切除后，不能接受辅助放疗。术后辅助放疗改善了肿瘤切除不完全的患者的预后。不典型的CN完全切除后，不建议进行辅助放疗，并且需要密切随访影像学检查。我们的发现可以帮助指导有关中枢神经系统治疗的决策，并可能最大程度地提高对中枢神经系统患者的治疗益处。彻底的肿瘤切除应该是CN治疗的首选。完全切除后，不能接受辅助放疗。术后辅助放疗改善了肿瘤切除不完全的患者的预后。不典型的CN完全切除后，不建议进行辅助放疗，并且需要密切随访影像学检查。我们的发现可以帮助指导有关中枢神经系统治疗的决策，并可能最大程度地提高对中枢神经系统患者的治疗益处。不典型的CN完全切除后，不建议进行辅助放疗，并且需要密切随访影像学检查。我们的发现可以帮助指导有关中枢神经系统治疗的决策，并可能最大程度地提高对中枢神经系统患者的治疗益处。不典型的CN完全切除后，不建议进行辅助放疗，并且需要密切随访影像学检查。我们的发现可以帮助指导有关中枢神经系统治疗的决策，并可能最大程度地提高对中枢神经系统患者的治疗益处。